A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00222794|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : August 31, 2010
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia Schizoaffective Disorder||Drug: Atomoxetine (Strattera)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||66 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder|
|Study Start Date :||November 2003|
|Actual Study Completion Date :||July 2006|
- To examine efficacy of atomoxetine as an adjunct agent in treatment of negative symptoms in subjects with schizophrenia or schizoaffective disorder.
- To examine the effect of atomoxetine therapy on quality of life
- To examine safety of adjunctive treatment with atomoxetine
- To examine the effects of atomoxetine therapy on other domains of psychopathology (positive symptoms, depressive symptoms, general psychopathology).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00222794
|United States, Pennsylvania|
|Western Psychiatric Institute and Clinic|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Rohan Ganguli, MD||University of Pittsburgh|